Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for amyloid-positive adults at risk of Alzheimer's disease
ISRCTN71283871Phase 2Active, not recruiting
- Sponsor
- Imperial College London
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Semaglutide with Matching placebo (2 arms). Primary endpoint: Annualised change in cortical tau at week 52. Started Aug 2022; status: active, not recruiting.
02
Drugs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ISRCTN71283871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN71283871.